Novel peptide-doxorubucin conjugates for targeting breast cancer cells including the multidrug resistant cells
Rania Soudy1, Christopher Chen, Kamaljit Kaur
1Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta , Edmonton, Alberta, T6G 2E1, Canada.
Abstract:
The efficacy of chemotherapeutic doxorubucin (Dox) in cancer treatment is limited by two main factors, nonspecific toxicity and the emergence of tumor resistance. To overcome these hurdles, in this study peptide-Dox conjugates were prepared. A decapeptide 18-4a (NH₂-WxEAAYQkFL-CONH₂) [corrected] with high specificity for breast cancer cells and improved proteolytic stability was conjugated to Dox to give peptide-Dox ester (1) and amide (2) conjugates. Cell uptake studies showed that the conjugates were 6-10 times selective for breast cancerous cells (MCF-7 and MDA-MB-435) over noncancerous cells (HUVECs and MCF-10A). Conjugate 1 displayed similar toxicity as free Dox toward the breast cancerous cells and was about 40 times less toxic toward the noncancerous cells and 4-fold more toxic toward the Dox resistant MDA-MB-435-MDR cells than the free Dox. These data suggest that conjugate 1 can be used as a potential prodrug for improving the therapeutic index of Dox and potentially many other cytotoxic drugs.
Insights
Researchers developed peptide-doxorubicin (Dox) conjugates to combat cancer treatment limitations. These conjugates show high selectivity for breast cancer cells, reduced toxicity in healthy cells, and effectiveness against resistant tumors.
Area of Science:
- Biochemistry
- Medicinal Chemistry
- Oncology
Background:
- Chemotherapeutic doxorubicin (Dox) efficacy is hindered by nonspecific toxicity and tumor resistance.
- Developing targeted drug delivery systems is crucial for improving cancer treatment outcomes.
Purpose of the Study:
- To synthesize and evaluate peptide-doxorubicin conjugates for enhanced breast cancer therapy.
- To overcome doxorubicin's limitations of toxicity and drug resistance.
Main Methods:
- Conjugation of a breast cancer-specific decapeptide (18-4a) to doxorubicin to form ester (1) and amide (2) conjugates.
- In vitro cell uptake studies using breast cancer cell lines (MCF-7, MDA-MB-435) and noncancerous cell lines (HUVECs, MCF-10A).
- Cytotoxicity assays were performed on both sensitive and doxorubicin-resistant cancer cells.
Main Results:
- Peptide-Dox conjugates demonstrated 6-10 times greater selectivity for breast cancer cells over noncancerous cells.
- Conjugate 1 exhibited similar toxicity to free Dox in cancer cells but was 40 times less toxic to noncancerous cells.
- Conjugate 1 showed 4-fold increased toxicity against doxorubicin-resistant MDA-MB-435-MDR cells compared to free Dox.
Conclusions:
- Peptide-Dox conjugate 1 represents a promising prodrug strategy for enhancing doxorubicin's therapeutic index.
- This approach holds potential for improving the efficacy of various cytotoxic drugs in cancer treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers